Park Avenue Securities LLC Has $713,000 Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Park Avenue Securities LLC cut its position in United Therapeutics Co. (NASDAQ:UTHR) by 11.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,314 shares of the biotechnology company’s stock after selling 300 shares during the period. Park Avenue Securities LLC’s holdings in United Therapeutics were worth $713,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Signaturefd LLC boosted its position in United Therapeutics by 4.7% in the fourth quarter. Signaturefd LLC now owns 663 shares of the biotechnology company’s stock valued at $234,000 after buying an additional 30 shares in the last quarter. Parallel Advisors LLC lifted its position in shares of United Therapeutics by 2.8% during the fourth quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company’s stock worth $385,000 after purchasing an additional 30 shares in the last quarter. Anchor Investment Management LLC lifted its position in shares of United Therapeutics by 12.0% during the fourth quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 30 shares in the last quarter. Great Lakes Advisors LLC lifted its position in shares of United Therapeutics by 1.6% during the fourth quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company’s stock worth $697,000 after purchasing an additional 31 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund lifted its position in shares of United Therapeutics by 0.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company’s stock worth $3,214,000 after purchasing an additional 33 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on UTHR. Bank of America reduced their target price on shares of United Therapeutics from $321.00 to $315.00 and set a “neutral” rating on the stock in a research report on Wednesday. JPMorgan Chase & Co. reduced their target price on shares of United Therapeutics from $355.00 to $350.00 and set an “overweight” rating on the stock in a research report on Thursday, May 1st. Wells Fargo & Company reiterated an “equal weight” rating and set a $314.00 target price (down from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Cantor Fitzgerald began coverage on shares of United Therapeutics in a research report on Monday, June 2nd. They set an “overweight” rating and a $405.00 target price on the stock. Finally, Morgan Stanley upped their target price on shares of United Therapeutics from $346.00 to $348.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 1st. Four equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $393.08.

Insider Buying and Selling at United Therapeutics

In other news, Director Tommy G. Thompson sold 2,500 shares of the stock in a transaction on Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the sale, the director now owns 8,480 shares of the company’s stock, valued at $2,703,424. This represents a 22.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction on Thursday, April 17th. The stock was sold at an average price of $283.78, for a total transaction of $3,121,580.00. Following the sale, the executive vice president now directly owns 36,781 shares of the company’s stock, valued at $10,437,712.18. This represents a 23.02% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 68,500 shares of company stock valued at $20,828,390. Corporate insiders own 10.30% of the company’s stock.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $283.35 on Friday. United Therapeutics Co. has a 52 week low of $266.98 and a 52 week high of $417.82. The company has a market capitalization of $12.78 billion, a PE ratio of 12.44, a PEG ratio of 0.97 and a beta of 0.57. The company has a 50 day moving average price of $300.50 and a two-hundred day moving average price of $330.86.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating the consensus estimate of $6.29 by $0.34. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. During the same quarter in the prior year, the firm earned $6.17 earnings per share. The business’s quarterly revenue was up 17.2% on a year-over-year basis. On average, sell-side analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.